β-ccb

benzodiazepine receptor ligand

CCB02 is a selective CPAP-tubulin interaction inhibitor (IC50: 689 nM) with anti-tumor activity, showing no inhibition on cell cycle- and centrosome-related kinases, nor affecting the phosphorylation status of Aurora-A, CDK2, Plk1, Plk2, and CHK1.

TriGalNAc CBz is a GalNAc derivative. As an ASGPR ligand, tri-GalNAc targets lysosomes in mRNA drug delivery and LYTAC studies.L-DABA hydrobromide.

ICCB280 was capable of inducing differentiation and apoptosis of ATRA-resistant patient blasts strongly signify that the activity of this compound can overcome resistance to other current therapies for AML with an unfavorable prognosis.

C-NH-Boc-C-Bis-(C-PEG1-Boc) is a versatile alkyl/ether-based PROTAC linker used for synthesizing PROTACs [1].

C-NH-Boc-C-Bis-(C1-PEG1-PFP), a polyethylene glycol (PEG)-derived PROTAC linker, is utilized in the synthesis of PROTACs [1].

PROTAC Cbl-b-IN-1 is a PROTAC that targets Cbl-b. It is composed of the PROTAC targeting protein ligand Cbl-b-IN-21, PROTAC Linker Cbz-Pip-2C-Pip-C-Pip, and the E3 ubiquitin ligase ligand (3S)Lenalidomide-5-Br. The conjugate of the E3 ubiquitin ligase ligand and Linker is (3S)Lenalidomide-5-Pip-C-Pip-2C-Pip.

PROTACCB1R Degrader-1 is a potent and selective CB1R PROTAC degrader that employs the ubiquitin-proteasome system (UPS) to facilitate CB1R degradation, showing a DC50 of 3.37 μM in MCF-7 cells while exhibiting no effect on CB2R. It reduces CB1R-associated downstream signaling pathways (p-AKT, p-ERK, BCL2, and MCM5), thus inhibiting breast cancer cell proliferation and inducing apoptosis. PROTACCB1R Degrader-1 is applicable for breast cancer-related research.

PROTAC CBP/P300 Degrader-1 is an effective compound that potently degrades CBP/P300, significantly reducing cell viability in various cancer cell lines.

C(Cbz)-acetic acid is a useful organic compound for research related to life sciences and the catalog number is T64653.

SGC-CBP30 is an effective CREBBP/EP300 inhibitor (IC50: 21/38 nM).

ICCB-19 hydrochloride (ICCB-19 HCl) is an inhibitor of TRADD (TNFRSF1A Associated Via Death Domain). It binds to a pocket on the N-terminal TRAF2-binding domain of TRADD (TRADD-N), which interacts with the C-terminal domain (TRADD-C) and TRAF2 to modulate the ubiquitination of RIPK1 and beclin 1.